Boryeong announced that it held the groundbreaking ceremony for the "Second Anticancer Injection Building," a facility expansion for anticancer drug production, on the 12th at its pharmaceutical manufacturing complex, the "Boryeong Yeosu Campus," in Yeosu, Chungcheongnam-do. The company aims to leap into a global hub for cytotoxic anticancer drugs through this project.
Boryeong plans to invest approximately 50 billion won to fully commence construction of the Second Anticancer Injection Building. Once completion is achieved in the second half of 2028, the Yeosu Campus's annual production capacity for anticancer injections will expand by more than double, from the existing 6 million vials (bottles) to 13.2 million vials.
Through this, Boryeong will secure not only a stable domestic supply of cytotoxic anticancer drugs but also lay the foundation for a substantial expansion of overseas supply. The company is determined to transform the Yeosu Campus from an anticancer drug production facility focused on the domestic market into a "global strategic hub" in the cytotoxic anticancer drug sector, encompassing multi-product and multi-formulation production as well as overseas supply.
The Yeosu Campus already plays a role in the global supply chain through contract development and manufacturing organization (CDMO) services. In May of last year, Boryeong began its first overseas CDMO supply by providing "Alimta," produced at the Yeosu Campus, to the Taiwanese pharmaceutical company Lotus. The company has also signed a CDMO contract with Jurek Pharma and will supply Alimta to seven Southeast Asian countries starting in 2027.
Cytotoxic anticancer drugs are a major foundation of cancer treatment, but global supply disruptions have occurred due to complex manufacturing processes and profitability issues.
In response, Boryeong plans to expand its role as a "global supplier of cytotoxic anticancer drugs," further strengthening its domestic and international supply capabilities for essential anticancer drugs and accelerating the expansion of its global business.
Boryeong has served as the "largest domestic supplier" in the domestic cytotoxic anticancer drug market, holding a 55% market share (based on IQVIA data for 2025). The original (originator) anticancer drugs "Gemzar" and "Alimta" have completed the transition to in-house production following their acquisition. "Taxotere," whose acquisition was completed in May of this year, is being sequentially transitioned to production at the Yeosu Campus. Based on the production capabilities built through these efforts, Boryeong has established a business model that re-supplies original anticancer drugs overseas through CDMO and exports.
Meanwhile, the Yeosu Campus is a smart factory (intelligent plant) equipped with advanced manufacturing equipment and automation systems, ensuring efficiency across pharmaceutical production and world-class quality competitiveness. Following its acquisition of "EU-GMP" (European Good Manufacturing Practice) certification for its anticancer injection production facility from the European Medicines Agency (EMA) in 2023, the company recently received EU-GMP certification for its solid oral dosage form production facility as well.
Boryeong CEO Kim Jung-gyun stated, "The Second Anticancer Injection Building will be a key production hub driving Boryeong's global business expansion based on cytotoxic anticancer drugs, and a foundation supporting the global essential medicine supply chain." He added, "We will grow the Yeosu Campus into a truly leading global base for supplying cytotoxic anticancer drugs," emphasizing, "We will build production capabilities to supply cytotoxic anticancer drugs most stably and in the largest quantities in the global market, ensuring that essential medicines are delivered without interruption to patients who need them."
in THEBIO
